Increased brain activation in response to odors in patients with hyposmia after theophylline treatment demonstrated by fMRI

Journal of Computer Assisted Tomography

Volumn 22, Issue 5, 1998, Pages 760-770

  Levy, Lucien M ^a,c   Henkin, Robert I ^b   Lin, Chin S ^a   Hutter, Alf ^a   Schellinger, Dieter ^a  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^b Taste and Smell Clinic   (United States)

^c NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Brain; Magnetic resonance imaging, functional; Olfaction; Theophylline

Indexed keywords

ACTIVATION ANALYSIS; CHEMICAL ACTIVATION; MAGNETIC RESONANCE IMAGING; ODORS; PATIENT TREATMENT;

AFTER-TREATMENT; BRAIN ACTIVATION; BRAIN AREAS; BRAIN SCAN; FRONTAL LOBES; MAGNETIC RESONANCE IMAGING, FUNCTIONAL; MEDICAL THERAPY; OLFACTION; PSYCHO-PHYSICAL TESTS; THEOPHYLLINE;

BRAIN;

NITROBENZENE; PENTYL ACETATE; PYRIDINE; THEOPHYLLINE; THIOPHENE;

ADULT; AGED; ARTICLE; BRAIN; CASE REPORT; CONTROLLED STUDY; DRUG BLOOD LEVEL; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; ODOR; OLFACTORY DISCRIMINATION; PRIORITY JOURNAL; SMELLING DISORDER;

EID: 0031696534     PISSN: 03638715     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004728-199809000-00019     Document Type: Article

References (69)

1. Henkin RI. Evaluation and treatment of human olfactory dysfunction. In: English GM, ed. Otolaryngology, vol 2. Philadelphia: Lippincott, 1993:1-86.
2. Henkin RI, Smith FR. Hyposmia in acute viral hepatitis. Lancet 1971;1:823-6.
3. Henkin RI. The role of adrenal corticosteroids in sensory processes. In: Blaschko H, Sayers G, Smith AD, eds. Adrenal gland. Washington, DC: Amer. Physiol. Soc., 1975:209-30. (Handbook of physiology; endocrinology, vol 6).
4. Henkin RI. The role of adrenal corticosteroids in sensory processes. In: Blaschko H, Sayers G, Smith AD, eds. Adrenal gland. Washington, DC: Amer. Physiol. Soc., 1975:209-30. (Handbook of physiology; endocrinology, vol 6).
5. Cain WS, Gent JS, Catalanotto FA, Goodspeed RB. Clinical evaluation of olfaction. Am J Otolaryngol 1983;4:252-6.
6. Murphy C, Gilmore MN, Seery CS, Salmon DP. Olfactory thresholds are associated with degree of dementia in Alzheimer's disease. Neurobiol Aging 1990;11:465-9.
7. Doty RL. Olfactory dysfunction in neurodegenerative disorders. In: Getchell TV, Doty RL, Bartoshuk LM, Snow JB Jr, eds. Smell and taste in health and disease. New York: Raven Press, 1991: 735-51.
8. McConnell RJ, Mendedez CW, Smith FR, Henkin RI, Rivlin RS. Defects of taste and smell in patients with hypothyroidism. Am J Med 1975;59:354-64.
9. Smith DB, Allison T, Goff WR, Principato JJ. Human odorant evoked responses: effects of trigeminal or olfactory deficits. Electroencephalogr Clin Neurophysiol 1971;30:313-7.
10. Gerull G, Giesen M, Mrowinski D. Registerung olfactorish evozierter Potentiale fur die Klinische diagnostik. EEG-EMG 1975;6: 37-40.
11. Kobal G. Olfactory event-related potentials in the diagnosis of smell disorders. In: Kurihara K, Suzuki N, Ogawa H, eds. Olfaction and taste XI. Tokyo: Springer-Verlag, 1993:626-30.
12. Lorig TS, Schwartz GE. Brain and odor I: alteration of human EEG by odor administration. Psychobiology 1988;16:281-4.
13. Klemm WR, Lutes SD, Hendrix DV, Warrenburg S. Topographical EEG maps of human responses to odors. Chem Sens 1992;17: 347-61.
14. Aufferman H, Mathe F, Gerull G, Mrowinski D. Olfactory evoked potentials and contingent negative variation simultaneously recorded for diagnosis of smell disorders. Ann Otol Rhinol Laryngol 1993;102:6-10.
15. Tonoike M. Olfactory event-related potentials and olfactory neuromagnetic fields in humans. In: Kurihara K, Suzuki N, Ogawa H, eds. Olfaction and taste XI. Tokyo: Springer-Verlag, 1993:664-7.
16. Henkin RI. Olfaction in human disease. In: English GM, ed. Loose-leaf series of otolaryngology. New York: Harper and Row, 1982: 1-39.
17. Henkin RI. A clinical trial of treatment for hyposmia in patients with head injury. Clin Res 1991;39:406A.
18. Levy LM, Henkin RI, Hutter A, Lin CS, Martins D, Schellinger D. Functional MRI of human olfaction. J Comput Assist Tomogr 1997;21:849-56.
19. Levy LM, Henkin RI, Hutter A, Lin CS, Schellinger D. Mapping brain activation to odorants in patients with hyposmia by functional magnetic resonance imaging. J Comput Assist Tomogr 1998; 22:96-103.
20. Henkin RI. Concepts of therapy in taste and smell dysfunction: repair of sensory receptor function as primary treatment. In: Kurihara K, Suzuki N, Ogawa H, eds. Olfaction and taste XI. Tokyo: Springer-Verlag, 1994:568-73.
21. Levy LM, Bartsch AJ, Rajan S, Schellinger D, Henkin RI, MRI of olfactory structures: normal subjects and patients with olfactory dysfunction. Neuroradiology 1995;37(suppl):25-6.
22. Voris HK. Craniocerebral trauma. In: Baker AB, Baker LH, eds. Clinical neurology, vol 2. New York: Harper and Row, 1978:17.
23. Strich SJ. Shearing of nerve fibres as a cause of brain damage due to head injury. Lancet 1961:443-8.
24. Zusho H. Post traumatic anosmia. Acta Otolaryngol 1982;108: 90-2.
25. Adams RD, Victor M. Principles of neurology. New York: McGraw-Hill, 1993:202.
26. Nakashima T, Kimmelman CP, Snow JB Jr. Histopathology of the olfactory pathway due to ischemia. Laryngoscope 1984;94:171-5.
27. Summer D. Disturbance of the sense of smell and taste after head injuries: II. Injuries of the brain and skull. In: Vinken PJ, Bruyn GW, eds. Handbook of clinical neurology, vol 24. New York: Elsevier, 1975:1-25.
28. Thompson WJ. Cyclic nucleotide phosphodiesterases: pharmacology, biochemistry and function. Pharmacol Ther 1991;51:13-33.
29. Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 1995;75:725-48.
30. Kurihara K, Koyama N. High activity of adenyl cyclase in olfactory and gustatory organs. Biochem Biophys Res Commun 1972; 48:30-4.
31. Pace U, Hanski E, Salomon Y, Lancet D. Odorant-sensitive adenylate cyclase may mediate olfactory reception. Nature 1985;316: 255-8.
32. Anholt RRH. Molecular neurobiology of olfaction. Crit Rev Neurobiol 1993;7:1-22.
33. Stone EA, Herrera AS. Alpha-adrenergic modulation of cyclic AMP function in rat CNS: highest level in olfactory bulb. Brain Res 1986;384:401-3.
34. Kurahashi T, Kaneko A. High density cAMP-gated channels at the ciliary membrane in the olfactory receptor cell. Neuroreport 1991; 2:5-8.
35. Meneose A, Dodd G, Poynder TM. Evidence of the specific involvement of cyclic AMP in the olfactory transduction mechanism. Biochem Biophys Res Commun 1977;77:671-7.
36. Bakalyar HA, Reed RR. Identification of a specialized adenyl cyclase that may médiate odorant detection. Science 1990;250: 1403-6.
37. Nakamura T, Gold GH. A cyclic nucleotide-gated conductance in olfactory receptor cilia. Nature 1987;325:442-4.
38. Dhallan RS, Yau KW, Schrader KA, Reed RR. Primary structure and functional expression of a cyclic nucleotide-gated channel from olfactory neurons. Nature 1990;347:184-7.
39. Ludwig J, Margalit T, Eismann E, Lancet D, Kaupp UB. Primary structure of cAMP-gated channel from bovine olfactory epithelium. FEBS Lett 1990;270:24-9.
40. Firestein S, Zufall F, Shepherd GM. Single odor-sensitive channels in olfactory receptor neurons are also gated by cylic nucleotides. J Neurosci 1991;11:3565-72.
41. Frings S, Lindemann B. Current recording from sensory cilia of olfactory receptor cells in situ. I. The neuronal response to cyclic nucleotides. J Gen Physiol 1991;97:1-16.
42. Jones DT, Reed RR. Golf: an olfactory neuron-specific G protein involved in odorant signal transduction. Science 1989;244:790-5.
43. Buck L, Axel R. A novel multigene family may encode odorant receptors: a molecular basis for odor recognition. Cell 1991;65: 175-87.
44. Gunning PW, Letourneau PC, Landreth GE, Shooter EM. The action of nerve growth factor and dibutyryl adenosine cyclic 3′:5′-monophosphate on rat pheochromocytoma reveals distinct stages in the mechanisms underlying neurite outgrowth. J Neurosci 1981; 1:1085-95.
45. Yankner BA, Shooter EM. The biology and mechanism of action of nerve growth factor. Annu Rev Biochem 1982;51:845-68.
46. Henkin RI, Martin BM, Agarwal RP. Carbonic anhydrase VI deficiency: a viral induced enzyme disorder amenable to treatment with exogenous zinc. J Invest Med 1995;43(suppl 2):242A.
47. Daly J. Adenosine receptors: targets for future drugs. J Med Chem 1982;25:197-207.
48. Fredholm BB. Theophylline actions on adenosine receptors. Eur J Respir Dis 1980;61(suppl 109):29-36.
49. Higbee MD, Kumar M, Galant SP. Stimulation of endogenous catecholamine release by theophylline: a proposed additional mechanism of theophylline effects. J Allergy Clin Immunol 1988; 92:146-54.
50. Berkowitz BA, Tarver JH, Spector S. Release of norepinephrine in the central nervous system by theophylline and caffeine. Eur J Pharmacol 1970;10:64-71.
51. Watanabe H, Uramoto H. Caffeine mimics dopamine receptor agonists without stimulation of dopamine receptors. Neuropharmacology 1986;25:577-81.
52. Zarrindast MR, Heidavi MR. On the mechanisms by which theophylline changes core body temperature in mice. Eur J Pharmacol 1994;257:13-20.
53. Berkowitz BA, Spector S. The effect of caffeine and theophylline on the disposition of brain serotonin in the rat. Eur J Pharmacol 1971;16:322-5.
54. Waldeck B. Some effects of caffeine and aminophylline on the turnover of catecholamines in the brain. J Pharm Pharmacol 1971; 23:824-30.
55. Nagaoka H, Sakurada S, Sakurada T, et al. Theophylline-induced nociceptive behavioral response in mice: possible indirect interaction with spinal N-methyl-D-aspartate receptors. Neurochem Int 1993;22:69-74.
56. Ghosh SK, Poddar MK. δ-9-Tetrahydrocannabinol inhibits the binding of theophylline to mammalian neuronal and non-neuronal membranes. Biochem Pharmacol 1993;45:1725-8.
57. Kolbeck RC, Spear WA, Carrier GO, Bransome ED. Apparent irrelevance of cyclic nucleotides to the relaxation of tracheal smooth muscle induced by theophylline. Lung 1979;156:173-83.
58. Horrobin DT, Manku MS, Frank DJ, Hamet P. Methylxanthine phosphodiesterase inhibitors behave as prostaglandin antagonists in a perfused rat mesenteric preparation. Prostaglandins 1977;13: 33-40.
59. Barnes PJ. Methylxanthine and phosphodiesterase inhibitors in asthma and rhinitis. In: Busse WW, Holgate ST, eds. Asthma and Rhinitis. Cambridge: Blackwell, 1995:1268.
60. Spatafora M, Chiappara G, Merendino AM, D'Amico D, Bellia V, Bonsignore G. Theophylline suppresses the release of tumour necrosis factor-α by blood monocytes and alveolar macrophages. Eur Respir J 1994;7;223-8.
61. Nielson CP, Crawley JJ, Morgan ME, Vestal RE. Polymorpho-nuclear leukocyte inhibition by therapeutic concentrations of theophylline is mediated by cyclic 3′,5′ adenosine monophosphate, Am Rev Respir Dis 1988;37:25-30.
62. Shohat B, Voloritz B, Varsano I. Induction of suppressor T cells in asthmatic children by theophylline treatment. Clin Allergy 1983; 13:487-93.
63. Scordamaglia A, Ciprandi G, Ruffoni S, et al. Theophylline and the immune response: in vitro and in vivo effects. Clin Immunol Immunpathol 1988;48:238-46.
64. Coskey LA, Bitting J, Roth MD. Inhibition of natural killer cell activity by therapeutic levels of theophylline. Am J Respir Cell Mol Biol 1993;9:639-65.
65. Didier M, Aussel C, Ferrua B, Fehlman M. Regulation of interleukin 2 synthesis by cAMP in human T cells. J Immunol 1987; 139:1179-84.
66. Bloom F. The role of cyclic nucleotides in central synaptic function. Rev Physiol Biochem Pharmacol 1975;74:1-103.
67. Sattin A, Rall TW. The effect of adenosine and adenine nucleotides on the adenosine 3′,5′-phosphate content of guinea pig cerebral cortex slices. Mol Pharmacol 1970;6:13-23.
68. Stone TW, Taylor DA. An electrophysiological demonstration of a synergistic interaction between norepinephrine and adenosine in rat cerebral cortex. J Physiol (Lond) 1977;266:523-43.
69. Levy LM, Hutter A, Lin CS, Owen D, Schellinger D, Henkin RI. Role of frontal cortex in recognition of olfactory stimuli. J Invest Med 1996;44:228A.